149 compounds. Every one graded.

Fat-targeting hGH fragment for metabolic support

AOD9604 is a synthetic peptide fragment derived from the C-terminal region of human growth hormone (amino acids 176–191), developed originally by Monash University as an anti-obesity drug. It mimics the lipolytic (fat-burning) effects of growth hormone without stimulating IGF-1 production or promoting cell proliferation. Research suggests it stimulates fat breakdown and inhibits fat formation, with a favorable safety profile compared to full-length hGH.

Parathyroid hormone analog for bone building

Parathyroid hormone analog for severe osteoporosis anabolic therapy.

Salmon calcitonin for bone density

Calcium-regulating peptide for bone density & fracture prevention.

Myostatin blocker for serious muscle hypertrophy

FST 344 is a recombinant isoform of follistatin, a naturally occurring glycoprotein that binds and neutralizes myostatin and activin, two potent inhibitors of muscle growth. By suppressing these negative regulators, FST 344 promotes skeletal muscle hypertrophy, enhances recovery, and may support bone density. It has been investigated in gene therapy and preclinical contexts for muscular dystrophy and sarcopenia, though human clinical data remain very limited.

The Master Brake on Muscle Growth

GDF-8, also known as myostatin, is a TGF-β superfamily member that acts as a potent negative regulator of skeletal muscle mass. It limits muscle fiber size and number by inhibiting myoblast proliferation and differentiation. Research into myostatin inhibition has generated significant interest for applications in muscle wasting diseases, metabolic disorders, and athletic performance.